NEW YORK – San Diego-based Genome Insight said last week that its clinical laboratory has been accredited by the College of American Pathologists for its whole-genome sequencing services. The accreditation became effective in January. The firm said in November that it had raised $23 million in a Series B-2 financing round, which followed a Series B round that also raised $23 million in 2022.
Myriad Genetics said this week that it has completed its previously announced acquisition of select assets from Intermountain Health’s Intermountain Precision Genomics (IPG) laboratory business. Assets included the Precise Tumor Test, the Precise Liquid Test, and IPG’s CLIA-certified lab in St. George, Utah. IPG had previously offered Myriad’s Precise Tumor Test as TheraMap: Solid Tumor and moving forward, Myriad intends to operate TheraMap: Solid Tumor solely as Precise Tumor. Precise Liquid will launch later this year and IPG has completed all validation studies needed to support its local coverage determination. Additionally, it submitted clinical evidence of test performance for Precise Liquid for Medicare reimbursement in December.
UK genomics sample prep firm RevoluGen said this week that it has collaborated with LGC Biosearch Technologies to demonstrate a new protocol for automated bead-based high molecular weight DNA extraction. Under the collaboration, RevoluGen coupled its Fire Monkey chemistry with LGC's magnetic beads and LGC Oktopure liquid handling robot to extract HMW DNA from mammalian cells, followed by nanopore sequencing. "Our collaboration with LGC has demonstrated that our spin column-based technology can be transferred to a bead-based protocol with easy automation," RevoluGen CSO Georgios Patsos said in a statement. "We look forward to commercializing this new innovation."
In Brief This Week is a selection of news items that may be of interest to our readers but had not previously appeared on GenomeWeb.